Transgene to Present at the Cowen & Company 33rd Annual Healthcare Conference
Strasbourg, France, February 26, 2013 - Transgene S.A. (Euronext Paris: FR0005175080) today announced that Philippe Archinard, Chairman & Chief Executive Officer, will be presenting at the Cowen & Company Annual Healthcare Conference in Boston on Tuesday, March 5, 2013 at 11:20am, Eastern.
A copy of the management presentation will be accessible by visiting the Transgene website www.transgene.fr under the "Investor & Media" section.
Transgene, a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. Transgene has four compounds in phase 2 clinical development: TG4010 and Pexa-Vec (JX594/TG6006) having already completed initial phase 2 trials, TG4001 and TG4040. Transgene has concluded three strategic agreements for the development of its immunotherapy products: an option agreement with Novartis for the development of TG4010 to treat various cancers; an in-licensing agreement with US-based Jennerex, Inc. to develop and market Pexa-Vec, an oncolytic virus, and with the EORTC for the development of TG4001 to treat HPV induced head and neck cancers. Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available at www.transgene.fr.
Stéphane Boissel, Executive Vice President & CFO, +33 (0)3 88 27 91 02
Elisabetta Castelli, Director Investor Relations, +33 (0)3 88 27 91 21
Raimund Gabriel, +49 89 210 228 30
Shaun Brown, +44 207 148 5998
|TRANSGENE||Euronext Paris||3.0350 (c)||-0.49%||46 009|